Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18052333 | 0.81 | KDM4E (0.43) | KDM4EPIK3CDGRM2NQO2PER2 | |
| SCHEMBL9550092 | 0.76 | KDM4E (0.40) | KDM4EPIK3CDGRM2NQO2PER2 | |
| SCHEMBL5807789 | 0.76 | — | — | |
| SCHEMBL3020556 | 0.74 | — | — | |
| SCHEMBL8722184 | 0.73 | PIK3CD (0.41) | KDM4EPIK3CDGRM2NQO2PER2 | |
| SCHEMBL7276935 | 0.73 | KDM4E (0.38) | KDM4EPIK3CDGRM2NQO2PER2 | |
| SCHEMBL10961212 | 0.73 | KDM4E (0.38) | KDM4EPIK3CDGRM2NQO2PER2 | |
| SCHEMBL29954446 | 0.71 | KDM4E (0.46) | KDM4EPIK3CDGRM2NQO2PER2 | |
| SCHEMBL11421979 | 0.70 | PIK3CD (0.36) | KDM4EPIK3CDGRM2 | |
| SCHEMBL13966300 | 0.70 | TSHR (0.35) | KDM4EPIK3CDGRM2PER2CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304556-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150087600-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2015-03-26 | — | — | US | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304556-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | KDM4E 446/4885PIK3CD 2075/4885GRM2 565/4885 |
| US-20150087600-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | KDM4E 446/4885PIK3CD 2075/4885GRM2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.